Tvardi Therapeutics (LTS:0HTC) Operating Margin %: 0.00% (As of Mar. 2026)


What is Tvardi Therapeutics Operating Margin %?

Tvardi Therapeutics LTS:0HTC 12 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Tvardi Therapeutics ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Tvardi Therapeutics's Operating Income for the three months ended in Mar. 2026 was £-5.29 Mil. Tvardi Therapeutics's Revenue for the three months ended in Mar. 2026 was £0.00 Mil. Therefore, Tvardi Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Tvardi Therapeutics's Operating Margin % or its related term are showing as below:


LTS:0HTC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

Tvardi Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Tvardi Therapeutics's Operating Income for the three months ended in Mar. 2026 was £-5.29 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was £-21.89 Mil.


Tvardi Therapeutics  (LTS:0HTC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Tvardi Therapeutics Operating Margin % Related Terms


Tvardi Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Operating Margin % Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Operating Margin %
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTC vs PLRZ, BOLD, APLM: Operating Margin % Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tvardi Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Operating Margin % falls into.



Tvardi Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Tvardi Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-19.981 / 0
= %

Tvardi Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-5.288 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Tvardi Therapeutics (LTS:0HTC) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Tvardi Therapeutics' Operating Margin % too high?
Tvardi Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Tvardi Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Operating Margin % compare to PLRZ and BOLD?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #999999 out of 945 companies for Operating Margin %. This places Tvardi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.